Cargando…
PK/PD Mediated Dose Optimization of Emactuzumab, a CSF1R Inhibitor, in Patients With Advanced Solid Tumors and Diffuse‐Type Tenosynovial Giant Cell Tumor
Targeted biological therapies may achieve maximal therapeutic efficacy at doses below the maximum tolerated dose (MTD); therefore, the search for the MTD in clinical studies may not be ideal for these agents. Emactuzumab is an investigational monoclonal antibody that binds to and inhibits the activa...
Autores principales: | Smart, Kevin, Bröske, Ann‐Marie, Rüttinger, Dominik, Mueller, Claudia, Phipps, Alex, Walz, Antje‐Christine, Ries, Carola, Baehner, Monika, Cannarile, Michael, Meneses‐Lorente, Georgina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7589268/ https://www.ncbi.nlm.nih.gov/pubmed/32575160 http://dx.doi.org/10.1002/cpt.1964 |
Ejemplares similares
-
Phase Ib study of anti-CSF-1R antibody emactuzumab in combination with CD40 agonist selicrelumab in advanced solid tumor patients
por: Machiels, Jean-Pascal, et al.
Publicado: (2020) -
Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade
por: Gomez-Roca, Carlos, et al.
Publicado: (2022) -
Interactions in CSF1-Driven Tenosynovial Giant Cell Tumors
por: van IJzendoorn, David G.P., et al.
Publicado: (2022) -
Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy
por: Cannarile, Michael A., et al.
Publicado: (2017) -
Molecular Profiling of Atypical Tenosynovial Giant Cell Tumors Reveals Novel Non-CSF1 Fusions
por: Vougiouklakis, Theodore, et al.
Publicado: (2019)